Completed PHASE3 INTERVENTIONAL 1-arm NCT01558336

Schistosoma Haematobium Infections and Praziquantel

Schistosoma Haematobium Infections Among Schoolchildren in Central Sudan One Year After Treatment With Praziquantel

Sponsor: Hikma Pharmaceuticals LLC

Updated 5 times since 2017 Last updated: Jan 16, 2013 Started: Aug 31, 2008 Primary completion: Aug 31, 2012 Completion: Sep 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Schistosomiasis, this trial is completed. The trial is conducted by Hikma Pharmaceuticals LLC and has accumulated 5 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Aug 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hikma Pharmaceuticals LLC
University of Khartoum

Data source: University of Khartoum

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Al Salamania, Sudan